FDA moves BPC-157 to Category 1 by…?
As of Tue, 20 Oct 2026 16:01:44 UTC, Polymarket traders price Yes (51.0%). The market has $3K in volume and closes on Fri, 01 Jan 2027.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Yes | 51.0% | 51.0¢ | 49.0¢ |
Market details
- Venue: Polymarket
- Volume: $3K
- Liquidity: $144
- Closes:
Resolution rules
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Sources
Related markets
- Venezuela leader end of 2026?
- Who will leave their role in the Trump administration this year?
- Will Trump buy at least part of Greenland?
- Will marijuana be rescheduled?
- Who will be Trump's next Press Secretary?
- Will Americans receive tariff stimulus checks?
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.